Company newsCompany release
Gilead Sciences GILD
Gilead Sciences details Phase 3 IDEAL results for Livdelzi in PBC
The results cover people with PBC treated with Livdelzi in second-line treatment, according to the company.
GetSignal
Free on iOS and Android
Gilead Sciences said on November 5, 2026, that detailed results from the Phase 3 IDEAL study showed the majority of participants with PBC treated with Livdelzi (seladelpar) achieved the alkaline phosphatase (ALP) normalization composite endpoint.
The endpoint is defined as ALP at or below 1.0 times the upper limit of normal and a decrease of at least 15% from baseline.
Key facts
- Study
- Phase 3 IDEAL
- Treatment
- Livdelzi (seladelpar)
- Endpoint
- ALP at or below 1.0 times the upper limit of normal and at least 15% decrease from baseline
Source: The company's release on Business Wire, November 5, 2026.
Written by GetSignal with AI from the company's press release.
Not investment advice.
More company news
Gilead Sciences first, then the newest- Gilead Sciences to acquire oral IL-23R inhibitor HCXT-2001 from PepStar
GILD · Gilead Sciences · Company release ·
- Florida Power & Light doubles Saving Steps funding to $30 million
NEE · NextEra Energy · Company release ·